natgillin/translations-raw huggingface dataset:
Overdose with ceftazidime/avibactam can lead to neurological sequelae including encephalopathy, convulsions and coma, due to the ceftazidime component. 
Preveliko odmerjanje ceftazidima/avibaktama ima lahko zaradi ceftazidimske sestavine nevrološke posledice, vključno z encefalopatijo, konvulzijami in komo.
• Complicated intra-abdominal infection (cIAI) 
• zapletenih intraabdominalnih okužb (cIAI - complicated intra-abdominal infection),
Each vial contains ceftazidime pentahydrate equivalent to 2 g ceftazidime and avibactam sodium equivalent to 0.5 g avibactam. 
Ena viala vsebuje ceftazidim pentahidrat, ki ustreza 2 g ceftazidima, in natrijev avibaktamat, ki ustreza 0,5 g avibaktama.
No data are available on animal studies with ceftazidime. 
Podatkov o študijah ceftazidima na živalih ni.
Zavicefta is used in adults to treat: 
Za kaj uporabljamo zdravilo Zavicefta Zdravilo Zavicefta se uporablja pri odraslih za zdravljenje:
It is recommended that Zavicefta should be used to treat infections due to aerobic Gram-negative organisms in adult patients with limited treatment options only after consultation with a physician with appropriate experience in the management of infectious diseases (see section 4.4). 
Pri odraslih bolnikih z omejenimi možnostmi zdravljenja je zdravljenje okužb z aerobnimi gramnegativnimi bakterijami z zdravilom Zavicefta priporočljivo uporabiti le po posvetu z zdravnikom, ki ima ustrezne izkušnje z obvladovanjem infekcijskih bolezni (glejte poglavje 4.4).
The pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established. 
Farmakokinetika ceftazidima pri bolnikih s hudo okvaro jeter ni ugotovljena.
As ceftazidime and avibactam do not appear to undergo significant hepatic metabolism, the systemic clearance of either active substance is not expected to be significantly altered by hepatic impairment. 
Ker v jetrih ni pomembne presnove ceftazidima in avibaktama, ni pričakovati, da bi okvara jeter bistveno spremenila sistemski očistek enega ali drugega.
• yellowing of the whites of the eyes or skin sudden onset of a severe rash or blistering or peeling skin, possibly accompanied by a high fever or joint pain (these may be signs of more serious medical conditions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme or a condition known as DRESS, 
• nenaden pojav hudega izpuščaja, mehurjev ali lupljenja kože, lahko skupaj z močno zvišano telesno temperaturo ali bolečinami v sklepih (to so lahko znaki resnejših motenj, na primer toksične epidermalne nekrolize, Stevens-Johnsonovega sindroma, multiformnega eritema ali stanja, ki ga imenujemo "reakcija na zdravilo z eozinofilijo in sistemskimi simptomi" [DRESSDrug Reaction with Eosinophilia and Systemic Symptoms])
Very common: (may affect more than 1 in 10 people) 
Zelo pogosti: (pojavijo se lahko pri več kot 1 od 10 bolnikov)
Zavicefta should not be mixed with or physically added to solutions containing other medicinal products. 
Zdravila Zavicefta se ne sme mešati z raztopinami, ki vsebujejo druga zdravila, in se ga ne sme fizično dodajati takšnim raztopinam.
• infections of the stomach and gut (abdomen) 
• okužb želodca in črevesa (okužb v trebuhu),
The average increases in avibactam AUC are 3.8-fold and 7-fold in subjects with moderate and severe renal impairment, see section 4.2. 
Povprečno se AUC avibaktama pri bolnikih z zmerno okvaro ledvic zviša 3,8-krat in pri bolnikih s hudo okvaro ledvic 7-krat, glejte poglavje 4.2.
Hypersensitivity to any cephalosporin antibacterial agent. 
Preobčutljivost za kateri koli cefalosporinski antibiotik.
VIAL LABEL 
NALEPKA NA VIALI
No metabolism of avibactam was observed in human liver preparations (microsomes and hepatocytes). 
V preparatih človeških jeter (mikrosomi in hepatociti) niso opazili presnove avibaktama.
Animal studies with avibactam do not indicate harmful effects with respect to fertility (see section 5.3). 
Študije avibaktama na živalih ne kažejo škodljivih učinkov na plodnost (glejte poglavje
The pharmacokinetics of both ceftazidime and avibactam are approximately linear across the dose range studied (50 mg to 2000 mg) for a single intravenous administration. 
Po enkratni intravenski uporabi sta tako farmakokinetika ceftazidima kot avibaktama v raziskanem razponu (od 50 mg do 2000 mg) približno linearni.
Zavicefta is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1): 
Zdravilo Zavicefta je indicirano pri odraslih za zdravljenje naslednjih okužb (glejte poglavji 4.4 in
Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function (see section 4.4). 
Sočasno zdravljenje z velikimi odmerki cefalosporinov in nefrotoksičnih zdravil, npr. aminoglikozidov ali močnih diuretikov (npr. furosemida) lahko neugodno vpliva na delovanje ledvic (glejte poglavje 4.4).
• an increase in the level of some types of substances in your blood (called “creatinine” and 
• zvišanje ravni določenih snovi v krvi (imenovanih "kreatinin" in "sečnina").
Since a clinical interaction study of avibactam and probenecid has not been conducted, co-administration of avibactam with probenecid is not recommended. 
Kliničnih študij medsebojnega delovanja avibaktama in probenecida niso izvedli, zato sočasna uporaba avibaktama in probenecida ni priporočljiva.
Amount to be withdrawn 
Količina za izvlek celotna količina
This diagnosis should be considered in patients who present with diarrhoea during or subsequent to the administration of Zavicefta (see section 4.8). 
Na to diagnozo treba pomisliti pri vseh bolnikih, ki med uporabo zdravila Zavicefta ali po njej dobijo drisko (glejte poglavje 4.8).
• decrease in the number of red blood cells (haemolytic anaemia) - shown in blood tests 
• zmanjšanje števila rdečih krvnih celic (hemolitična anemija) - pokaže se na preiskavi krvi
Concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products such as aminoglycosides or potent diuretics (e.g. furosemide) may adversely affect renal function. 
Sočasno zdravljenje z velikimi odmerki cefalosporinov in nefrotoksičnih zdravil, npr. aminoglikozidov ali močnih diuretikov (npr. furosemida), lahko neugodno vpliva na delovanje ledvic.
Standard aseptic techniques should be used for solution preparation and administration. 
Za pripravo in dajanje raztopine je treba upoštevati standardne aseptične postopke.
Complicated intra-abdominal infections Gram-negative micro-organisms 
Zapletene intraabdominalne okužbe Gramnegativni mikroorganizmi
An infusion bag may contain any of the following: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, sodium chloride 4.5 mg/mL and dextrose 25 mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer's solution. 
Infuzijska vrečka lahko vsebuje kar koli od naslednjega: 0,9 % (9 mg/ml) raztopino natrijevega klorida za injiciranje, 5 % (50 mg/ml) raztopino glukoze za injiciranje, raztopino 4,5 mg/ml natrijevega klorida in 25 mg/ml glukoze za injiciranje (0,45 % natrijevega klorida in 2,5 % glukoze) ali raztopino Ringerjevega laktata.
Appropriate infusion diluents include: sodium chloride 9 mg/mL (0.9%) solution for injection, dextrose 50 mg/mL (5%) solution for injection, sodium chloride 4.5 mg/mL and dextrose 25 mg/mL solution for injection (0.45% sodium chloride and 2.5% dextrose) or Lactated Ringer's solution. 
Ustrezni vehikli za infuzijo so: 0,9 % (9 mg/ml) raztopina natrijevega klorida za injiciranje, 5 % (50 mg/ml) raztopina glukoze za injiciranje, raztopina 4,5 mg/ml natrijevega klorida in 25 mg/ml glukoze za injiciranje (0,45 % natrijevega klorida in 2,5 % glukoze) ali raztopina Ringerjevega laktata.
Ceftazidime does not interfere with enzymebased tests for glycosuria. 
Ceftazidim ne vpliva na encimske teste glikozurije.
Resistance 
Odpornost
Ceftazidime is not metabolised. 
Ceftazidim se ne presnavlja.
• The active substances are ceftazidime and avibactam. 
• Učinkovini sta ceftazidim in avibaktam.
Clostridium difficile colitis 
Driska, povezana s Clostridium difficile
Driving and using machines Zavicefta may make you feel dizzy. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Zavicefta vam lahko povzroči omotico.
Penetration of ceftazidime into the intact blood-brain barrier is poor. 
Ceftazidim slabo prodira skozi intaktno krvno-možgansko pregrado.
Avibactam and ceftazidime showed no in vitro cytochrome P450 induction at clinically relevant concentrations. 
Avibaktam in ceftazidim v klinično pomembnih koncentracijah in vitro nista inducirala citokroma P450.
Table 1 shows the recommended intravenous dose for patients with estimated creatinine clearance (CrCL) ≥ 51 mL/min (see sections 4.4 and 5.1). 
Preglednica 1 prikazuje priporočene intravenske odmerke za bolnike z ocenjenim očistkom kreatinina (CrCL) ≥ 51 ml/min ( glejte poglavji 4.4 in 5.1).
• infections of the bladder or kidneys called “urinary tract infections” 
• okužb mehurja ali ledvic, ki jih imenujemo "okužbe sečil",
• increase in the amount of some enzymes produced by your liver - shown in blood tests 
• zvišanje ravni nekaterih encimov, ki jih proizvajajo jetra - pokaže se na preiskavah krvi
Aseptic technique must be followed in preparing the infusion solution. 
Pri pripravi raztopine za infundiranje je treba upoštevati aseptični postopek.
How to use Zavicefta 
Kako uporabljati zdravilo Zavicefta
Zavicefta will be given to you by a doctor or a nurse, so it is unlikely you will be given the wrong dose. 
Če ste uporabili večji odmerek zdravila Zavicefta, kot bi smeli Zdravilo Zavicefta vam bo dal zdravnik ali medicinska sestra, zato ni verjetno, da bi dobili napačen odmerek.
• a water tablet called furosemide 
• tablete za odvajanje vode, imenovane furosemid,
• an antibiotic called chloramphenicol 
• antibiotik, imenovan kloramfenikol,
Ceftazidime is excreted unchanged into the urine by glomerular filtration; approximately 80-90% of the dose is recovered in the urine within 24 h. Avibactam is excreted unchanged into the urine with a renal clearance of approximately 158 mL/min, suggesting active tubular secretion in addition to glomerular filtration. 
Avibaktam se nespremenjen izloča v urin z ledvičnim očistkom približno 158 ml/min; to kaže, da poleg glomerulne filtracije poteka aktivna tubulna sekrecija.
Avibactam does not inhibit class B enzymes (metallo-β-lactamases) and is not able to inhibit many of the class D enzymes (see section 
Avibaktam ne zavira encimov razreda B (metalo-betalaktamaz) in ne more zavreti veliko encimov razreda D (glejte poglavje 5.1).
Avibactam showed no significant inhibition of cytochrome P450 enzymes in vitro. 
Avibaktam in vitro ni pomembno zavrl encimov citokroma P450.
If you are not sure, talk to your doctor or nurse before using Zavicefta. 
Če ste negotovi, se pred uporabo zdravila Zavicefta posvetujte z zdravnikom ali medicinsko sestro.
Table 2 shows the recommended dose adjustments for patients with estimated CrCL ≤ 50 mL/min (see sections 4.4 and 5.2). 
Preglednica 2 prikazuje priporočene prilagoditve odmerka za bolnike z ocenjenim očistkom kreatinina ≤ 50 ml/min (glejte poglavji 4.4 in 5.2):
No synergy or antagonism was demonstrated in in vitro drug combination studies with ceftazidime/avibactam and metronidazole, tobramycin, levofloxacin, vancomycin, linezolid, colistin and tigecycline. 
In vitro študije kombinacij s ceftazidimom/avibaktamom in metronidazolom, tobramicinom, levofloksacinom, vankomicinom, linezolidom, kolistinom in tigeciklinom niso pokazale ne sinergije ne antagonizma.
• significant decrease in the type of white blood cells used to fight infection - shown in blood tests 
• bistveno zmanjšanje vrste belih krvnih celic, ki premagujejo okužbe - pokaže se na preiskavi krvi
Gender and race The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race. 
Spol in rasa Spol in rasa nimata pomembnega vpliva na farmakokinetiko kombinacije ceftazidim/avibaktam.
Approximately 97% of the avibactam dose is recovered in the urine, 95% within 12 h. Less than 1% of ceftazidime is excreted via the bile and less than 0.25% of avibactam is excreted into faeces. 
Manj kot 1 % ceftazidima se izloči z žolčem in manj kot 0,25 % avibaktama se izloči v blato.
Dose of ceftazidime/avibactam 
Odmerek ceftazidima/avibaktama
Table 3 Frequency of adverse reactions by system organ class 
Pogostnost neželenih učinkov po organskih sistemih Organski sistem
Spectrum of activity of ceftazidime/avibactam 
Spekter delovanja ceftazidima/avibaktama
Parenteral medicinal products should be inspected visually for particulate matter prior to administration. 
Parenteralna zdravila je treba pred uporabo pregledati in se prepričati, da ne vsebujejo delcev.
Vulvovaginal candidiasis and Oral candidiasis) 
Infekcijske in parazitske bolezni kandidoza (vključno z vulvovaginalno kandidozo in oralno kandidozo)
Caution should be used if ceftazidime/avibactam is given to patients with a history of non-severe hypersensitivity to penicillins, monobactams or carbapenems. 
V primeru uporabe ceftazidima/avibaktama pri bolnikih z anamnezo preobčutljivosti na peniciline, monobaktame ali karbapeneme, ki ni huda, je potrebna previdnost.
Drug Reaction with Eosinophilia and Systemic Symptoms) 
StevensJohnsonov sindrom multiformni eritem angioedem reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS - Drug Reaction with Eosinophilia and Systemic
Total volume 
Odmerna shema
Pharmacotherapeutic group: Antibacterials for systemic use, ceftazidime, combinations, ATC code: J01DD52 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje infekcij, ceftazidim, kombinacije.
• decrease in the number of some types of blood cells (called “leucocytes”) - shown in blood tests 
• zmanjšanje števila nekaterih vrst krvnih celic (imenovanih "levkociti") - pokaže se na preiskavah krvi
• feeling sick (nausea) or being sick (vomiting) 
• slabost (navzea) ali bruhanje
However, the possibility that haemolytic anaemia could occur in association with Zavicefta treatment cannot be ruled out. 
V povezavi z zdravljenjem z zdravilom Zavicefta ni mogoče izključiti možnosti za hemolitično anemijo.
Dose recommendations are based on pharmacokinetic modelling Ceftazidime and avibactam are removed by haemodialysis (see sections 4.9 and 5.2). 
Ceftazidim in avibaktam se odstranjujeta s hemodializo (glejte poglavji 4.9 in 5.2).
Hepatic impairment No dosage adjustment is required in patients with hepatic impairment (see section 5.2). 
Okvara jeter Bolnikom z okvaro jeter odmerka ni treba prilagoditi (glejte poglavje 5.2).
No dosage adjustment is required in patients with mild renal impairment (estimated CrCL ≥ 51≤ 80 mL/min) (see section 5.2). 
Bolnikom z blago okvaro ledvic (ocenjeni očistek kreatinina od 51 do ≤ 80 ml/min) odmerka ni treba prilagoditi (glejte poglavje 5.2).
Additional antibacterial agents should be used when these pathogens are known or suspected to be contributing to the infectious process. 
Če je znano, ali obstaja sum, da so v infekcijsko dogajanje vpleteni ti patogeni, je treba uporabiti dodatna protibakterijska zdravila.
Dosing of Zavicefta on haemodialysis days should occur after completion of haemodialysis. 
Na dan hemodialize je treba zdravilo Zavicefta uporabiti po dokončani hemodializi.
0.75 g/0.1875 g Every 12 hours 
0,75 g/0,1875 g na 12 ur
The mean elimination half-life of ceftazidime ranged from 3.5 to 4 hours following intravenous bolus dosing with 2 g every 12 hours in elderly patients aged 80 years or older. 
Po uporabi intravenskih bolusnih odmerkov 2 g ceftazidima na 12 ur pri bolnikih, starih 80 let ali več, je bil njegov povprečni eliminacijski razpolovni čas od 3,5 do 4 ure.
No appreciable accumulation of ceftazidime or avibactam was observed following multiple intravenous infusions of 2000 mg/500 mg of ceftazidime/avibactam administered every 8 hours for up to 11 days in healthy adults with normal renal function. 
Pri zdravih odraslih z normalnim delovanjem ledvic niso zabeležili opaznega kopičenja ceftazidima ali avibaktama po večkratnih intravenskih infuzijah 2000 mg ceftazidima/500 mg avibaktama na 8 ur do 11 dni.
• increase in the number of a type of blood cell (called “lymphocytes”) - shown in blood tests 
• povečanje števila določene vrste krvnih celic (imenovanih "limfociti") - pokaže se na preiskavah krvi
Clostridium difficile-associated diarrhoea has been reported with ceftazidime/avibactam, and can range in severity from mild to life-threatening. 
Med zdravljenjem s ceftazidimom/avibaktamom je bila opisana driska zaradi Clostridium difficile, ki je lahko blaga do smrtno nevarna.
0.75 g/0.1875 g Every 48 hours 
0,75 g/0,1875 g na 48 ur
Common (≥1/100 and <1/10) Uncommon (≥1/1,000 and <1/100) Rare (≥1/10,000 and <1/1000) Very rare (<1/10,000) 
Občasni (≥ 1/1.000 in < 1/100)
Table 2 Recommended intravenous doses for patients with estimated CrCL ≤ 50 mL/min Estimated CrCL (mL/min) 
Priporočeni intravenski odmerek za bolnike z ocenjenim očistkom kreatinina ≤ 50 ml/min Ocenjeni očistek kreatinina (ml/min)
A total of 81 cUTI patients (7.4%) had bacteraemia at baseline. 
Bakteriemijo je izhodiščno imelo81 bolnikov (7,4 %) z zapleteno okužbo sečil.
Hospital-acquired pneumonia including ventilator-associated pneumonia Gram-negative micro-organisms 
Bolnišnična pljučnica, vključno s pljučnico zaradi uporabe respiratorja Gramnegativni mikroorganizmi
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity or genotoxicity. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih in genotoksičnosti ne kažejo posebnega tveganja za človeka.
If you get any side effects, talk to your doctor or nurse. 
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali medicinsko sestro.
Uncommon: (may affect up to 1 in 100 people) 
Občasni: (pojavijo se lahko pri največ 1 od 100 bolnikov)
In-vitro data indicate that the following species are not susceptible to ceftazidime/avibactam. 
Podatki in vitro kažejo, da za kombinacijo ceftazidim/avibaktam niso občutljive naslednje vrste:
0.75 g/0.1875 g Every 24 hours 
0,75 g/0,1875 g na 24 ur
What Zavicefta looks like and contents of the pack Zavicefta is a white to yellow powder for concentrate for solution for infusion in a vial. 
Zdravilo Zavicefta je bel do rumen prašek za koncentrat za raztopino za infundiranje v viali.
Complicated urinary-tract infections Gram-negative micro-organisms 
Zapletene okužbe sečil Gramnegativni mikroorganizmi
Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion 
Zavicefta 2 g/0,5 g prašek za koncentrat za raztopino za infundiranje
• tingling or numbness 
• mravljinčenje ali omrtvičenost
The steady-state volumes of distribution of ceftazidime and avibactam were about 22 L and 18 L, respectively in healthy adults following multiple doses of 2000 mg/500 mg ceftazidime/avibactam infused over 2 hours every 8 hours. 
Pri zdravih odraslih, ki so prejeli večkratne odmerke 2000 mg ceftazidima/500 mg avibaktama, infundirane v 2 urah vsakih 8 ur, sta bila njuna volumna porazdelitve v stanju dinamičnega ravnovesja približno 22 l (ceftazidim) in 18 l (avibaktam).
Neurological sequelae, including tremor, myoclonus, non-convulsive status epilepticus, convulsion, encephalopathy and coma, have occasionally been reported with ceftazidime when the dose has not been reduced in patients with renal impairment. 
Če bolnikom z okvaro ledvic niso zmanjšali odmerka ceftazidima, so med njegovo uporabo občasno poročali o nevroloških posledicah, med drugim o tremorju, mioklonusu, nekonvulzivnem epileptičnem statusu, konvulzijah, encefalopatiji in komi.
What Zavicefta contains 
Kaj vsebuje zdravilo Zavicefta
• raised itchy skin rash (“hives”) 
• dvignjen in srbeč izpuščaj na koži (“koprivnica”)
Skin and subcutaneous tissue disorders 
Bolezni kože in podkožja makulopapulozen izpuščaj urtikarija srbenje toksična epidermalna nekroliza
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproduction toxicity or genotoxicity. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, vpliva na sposobnost razmnoževanja in genotoksičnosti ne kažejo posebnega tveganja za človeka.
Table 1 Recommended intravenous dose for patients with estimated CrCL ≥ 51 mL/min Type of infection 
Priporočeni intravenski odmerek za bolnike z ocenjenim očistkom kreatinina ≥ 51 ml/min
Common: (may affect up to 1 in 10 people) 
Pogosti: (pojavijo se lahko pri največ 1 od 10 bolnikov)
What Zavicefta is 
Kaj je zdravilo Zavicefta
Dose regimen 
- Navodilo shranite.
• itchiness 
• omotica
It is unknown whether avibactam is excreted in human milk. 
Ceftazidim se v majhni količini izloča v materino mleko, za avibaktam pa ni znano, ali se izloča v materino mleko.
Zavicefta contains sodium 
Zdravilo Zavicefta vsebuje natrij
2 g/0.5 g 
2 g/0,5 g na 8 ur
oC. 
B.
Dilute before use 
Pred uporabo razredčite.
• stomach pain 
• bolečine v trebuhu
Haemolytic anaemia 
Bolezni imunskega sistema anafilaktična reakcija
1 g/0.25 g 
1 g/0,25 g na 8 ur
Tell your doctor straight away if you notice any of the following serious side effects - you may need urgent medical treatment: 
Če opazite katerega od naslednjih resnih neželenih učinkov, nemudoma obvestite zdravnika.
How to store Zavicefta 
Shranjevanje zdravila Zavicefta
Dosage strength ceftazidime/avibactam (mg) 
Velikost odmerka ceftazidim/avibaktam (mg)
To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process The total duration shown may include intravenous Zavicefta followed by appropriate oral therapy There is very limited experience with the use of Zavicefta for more than 14 days 
Če je znano, ali obstaja sum, da so v infekcijsko dogajanje vpleteni anaerobni patogeni, je treba to zdravilo uporabiti v kombinaciji z metronidazolom.
ZAVICEFTA 2 g/0.5g powder for concentrate for solution for infusion ceftazidime/avibactam 
Zavicefta 2 g/0,5 g prašek za koncentrat za raztopino za infundiranje ceftazidim/avibaktam
ZAVICEFTA 2 g/0.5 g powder for concentrate ceftazidime/avibactam 
ZAVICEFTA 2 g/0,5 g prašek za koncentrat ceftazidim/avibaktam i.v.
Talk to your doctor or nurse before using Zavicefta if: 
Pred začetkom uporabe zdravila Zavicefta se posvetujte z zdravnikom ali medicinsko sestro:
Susceptibility testing breakpoints 
Mejne vrednosti za testiranje občutljivosti
Nervous system disorders 
Bolezni živčevja glavobol omotica parestezije
Ceftazidime/avibactam use may cause development of a positive direct antiglobulin test (DAGT, or Coombs test), which may interfere with the cross-matching of blood and/or may cause drug induced immune haemolytic anaemia (see section 4.8). 
Kombinacija ceftazidim/avibaktam lahko povzroči pozitiven izvid direktnega antiglobulinskega testa (DAGT ali Coombsovega testa).
Tell your doctor that you are taking Zavicefta if you are going to have any tests. 
Če boste morali opraviti kakšne preiskave, morate zdravniku povedati, da dobivate zdravilo Zavicefta.
Controlled sodium diet 
Prehrana z omejitvijo natrija
Ceftazidime concentrations of 4 to 20 mg/L or more are achieved in the CSF when the meninges are inflamed. 
Če so meninge vnete, ceftazidim v cerebrospinalni tekočini doseže koncentracijo od 4 do 20 mg/l ali več.
• diarrhoea 
• driska
Talk to your pharmacist or doctor if you have been advised to have a low salt diet. 
Če so vam svetovali prehrano z nizko vsebnostjo soli, se posvetujte s farmacevtom ali zdravnikom.
ESRD including on haemodialysis 
Končna odpoved ledvic, vključno s hemodializo3
Dizziness 
Občutljivi
Paraesthesia 
Odmerjanje
The following indications have been justified: 
Potrjene so bile naslednje indikacije: